Artigo Revisado por pares

Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes

2009; Elsevier BV; Volume: 42; Issue: 7-8 Linguagem: Inglês

10.1016/j.clinbiochem.2008.12.016

ISSN

1873-2933

Autores

Yingchun Han, Edward Randell, Sudesh Vasdev, Vicki Gill, Matthew Curran, Leigh Anne Newhook, Marie Grant, Donna Hagerty, C. Schneider,

Tópico(s)

Diabetes, Cardiovascular Risks, and Lipoproteins

Resumo

Elevated advanced glycation endproducts (AGEs) are implicated in diabetic complications. Methylglyoxal-derived hydroimidazolone (MG-H) is one of the most abundant AGEs in vivo. Our objective was to develop a time-saving, specific method to measure free MG-H in plasma and determine its levels in complication-free young individuals with Type 1 diabetes (T1DM). The relationship of plasma free MG-H to hemoglobin A1C (A1C) and plasma methylglyoxal levels was also determined. A solid phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed, and free plasma MG-H levels were measured in 40 T1DM patients (DM group), aged 6–21 years, and 11 non-diabetics (ND group), 6–22 years. Methylglyoxal was measured using LC-MS/MS and A1C by a Tosoh G7 high-performance liquid chromatograph. Our method showed high recovery, sensitivity and short run-time. Plasma free MG-H (nmol/L) was higher (p < 0.001) in the DM group (1318 ± 569; mean ± standard deviation) as compared to the ND group (583 ± 419). Within the DM group, plasma free MG-H did not correlate with plasma methylglyoxal or A1C. Our LC-MS/MS method to measure free MG-H in plasma may be useful for future clinical application. The increased levels of free MG-H observed in individuals with TIDM are not merely the result of short term changes in glucose or methylglyoxal, but may reflect long-term alterations to tissue proteins.

Referência(s)
Altmetric
PlumX